Document Detail

Recent progress in the development of anthrax vaccines.
MedLine Citation:
PMID:  22360464     Owner:  NLM     Status:  In-Data-Review    
Bacillus anthracis is the etiological agent of anthrax. Although anthrax is primarily an epizootic disease; humans are at risk for contracting anthrax. The potential use of B. anthracis spores as biowarfare agent has led to immense attention. Prolonged vaccination schedule of current anthrax vaccine and variable protection conferred; often leading to failure of therapy. This highlights the need for alternative anthrax countermeasures. A number of approaches are being investigated to substitute or supplement the existing anthrax vaccines. These relied on expression of Protective antigen (PA), the key protective immunogen; in bacterial or plant systems; or utilization of attenuated strains of B. anthracis for immunization. Few studies have established potential of domain IV of PA for immunization. Other targets including the spore, capsule, S-layer and anthrax toxin components have been investigated for imparting protective immunity. It has been shown that co-immunization of PA with domain I of lethal factor that binds PA resulted in higher antibody responses. Of the epitope based vaccines, the loop neutralizing determinant, in particular; elicited robust neutralizing antibody response and conferred 97% protection upon challenge. DNA vaccination resulted in varying degree of protection and seems a promising approach. Additionally, the applicability of monoclonal and therapeutic antibodies in the treatment of anthrax has also been demonstrated. The recent progress in the direction of anthrax prophylaxis has been evaluated in this review.
Manpreet Kaur; Rakesh Bhatnagar
Related Documents :
22449784 - Rational design of vaccines: learning from immune evasion mechanisms of persistent viru...
22662104 - Correction: systems analysis of mva-c induced immune response reveals its significance ...
15902454 - The appropriateness of snowmobiling in national parks: an investigation of the meanings...
22296264 - Improved serological response to h1n1 monovalent vaccine associated with viral suppress...
11846424 - Presence of cytokines in biological preparations.
12631744 - Diphtheria s european come back.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Recent patents on biotechnology     Volume:  5     ISSN:  2212-4012     ISO Abbreviation:  Recent Pat Biotechnol     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2012-02-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101309942     Medline TA:  Recent Pat Biotechnol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  148-59     Citation Subset:  IM    
Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi - 110067, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involv...
Next Document:  Miniaturization in Biotechnology: Speeding up the Development of Bioprocesses.